Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...
A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...
Please provide your email address to receive an email when new articles are posted on . All-cause mortality in COPD patients was “strongly predicted” by diffusing capacity of the lung for carbon ...
Extending the use of a continuous positive airway pressure (CPAP) treatment in premature infants by two weeks significantly increases lung volume and lung diffusion capacity, according to a new study.
—Early evidence suggests promise for a novel COPD treatment using autologous P63+ lung progenitor cell. This small study found the bronchoscopic transplantation of cultured P63+ cells to be safe and ...
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback